| Thrombolytic Science, LLC (TSI) | |
| Type: | Private |
| Location: | Cambridge, MA |
| Industry: | Biotechnology |
| Homepage: | tsillc.net |
Thrombolytic Science, LLC (TSI) is a private, clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots.[1] Gurewich co-founded the company and the founding CEO is business person Alexis Wallace.[2]
TSI's lead drug candidate is a synergistic sequential dual therapy combination of mutant prourokinase (the precursor form of urokinase) and a small dose of tPA [Tissue Plasminogen Activator]. TSI is developing its dual therapy as a potential treatment for conditions caused by blood clots, initially for ischemic stroke[2] [3] and heart attacks.
The company completed a Phase I trial in The Netherlands in 2017.
The company raised $8 million by 2012 mostly from an undisclosed angel investor.[1] [2]